ERcast: Clinical Perspectives Podcast Preview
The summary below is from an episode of ERcast: Clinical Perspectives
Thromboembolic risk after cardioversion for acute atrial fibrillation or flutter is far lower than many clinicians were taught. In acute-onset AF or atrial flutter, 30-day post-cardioversion event rates are under 1%, and the biggest uncertainty is whether low-risk patients benefit from short-course oral anticoagulation at all.
Post-cardioversion Stroke Risk in Acute AF
- Thirty-day event rate: Across more than 14,000 cardioversions, thromboembolic events at 30 days were just 0.42%, reinforcing that acute AF/flutter cardioversion is a low-event pathway rather than a routinely high-risk one.
- Anticoagulation effect uncertainty: Oral anticoagulation did not show a clear reduction in post-cardioversion thromboembolism in the higher-quality pooled data, largely because event rates were very low in both treated and untreated groups.
- Risk score signal: The thromboembolic events that did occur clustered in patients with higher baseline stroke risk by CHA2DS2-VASc, while low-risk patients had extremely few events. We get into how that shapes bedside counseling in the episode.
- Acute onset population: Most included patients had AF or flutter of less than 48 hours' duration, making the data especially relevant to the common ED question of whether recent-onset dysrhythmia can be cardioverted safely.
- Guideline disagreement: Canadian, American, and European guidance diverges on routine anticoagulation after cardioversion, reflecting how limited the evidence remains despite reassuringly low absolute event rates.
- Shared decision making: For low-risk patients considering forgoing four weeks of anticoagulation, the conversation hinges on a very small absolute stroke risk balanced against bleeding, cost, and follow-up realities.
Subscribe to ERcast: Clinical Perspectives to listen to the episode.
References:
1.) Wong BM et al. Thromboembolic Events Following Cardioversion of Acute Atrial Fibrillation and Flutter: A Systematic Review and Meta-Analysis. CJEM 2021. PMID: 33715143
2.) Andrande et al. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2018. PMID: 30404743
3.) January CT et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019. PMID: 30703431
4.) Hindricks G et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery: The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2020 PMID: 32860505
Faculty
- Matthew DeLaney, MD, FACEP, FAAEM
Dr. Matthew DeLaney is an emergency medicine physician and educator based in Birmingham, Alabama. A native of Mobile, he earned his medical degree from the University of South Alabama and completed his emergency medicine residency at Maine Medical Center.Dr. DeLaney has experience in both community and academic emergency medicine and is known for his commitment to teaching and medical education. He lives in Birmingham with his wife, Erin, who is also a physician, and their two daughters.
- Salim Rezaie, MD
